This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Losing weight fast on GLP-1 drugs? Your hair could be the next thing to go

Dermatologists report increased hair loss among GLP-1 drug users experiencing rapid weight reduction. This side effect, often telogen effluvium, stems from nutritional deficiencies and metabolic stress. Many patients start these medications without proper medical supervision, influenced by social media trends. Studies show a high prevalence of hair shedding, particularly among women and significant weight losers. Doctors advise medical supervision and balanced nutrition to manage this temporary condition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iSpeEKr
via IFTTT

India's Second Leapfrog: From sick-care to AI-native health infrastructure

Just as India bypassed copper landlines to become a global mobile data leader, it can now bypass the West's CPT-coded sick-care bureaucracy and build AI-powered, personalised healthspan infrastructure for the world.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VWaiTPn
via IFTTT

GLP-1 demand stirs up hunger for obesity care talent

Demand for nutrition professionals is rapidly increasing across India. Hospitals and digital health platforms are hiring more dietitians and educators. This trend supports patients using new GLP-1 obesity medications. Specialized obesity care teams are expanding to meet growing patient needs. Long-term monitoring and lifestyle support are crucial for sustained health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SEy0he
via IFTTT

Jackson Labs' Baddi drug manufacturing licence restored after suspension

The unit's licence was cancelled in June after several women in Kota, Rajasthan, died allegedly due to spurious oxytocin injections supplied by the company's Punjab unit.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/agUXoKF
via IFTTT

Sun Pharma recalls eye drops in India after contamination scare

"Withdrawal of Product - Depopred2ML, Brinolar (BKC FREE), Brinzotim Eye Drops 5ML BKC FREE, Lotepred-5ML, Lotepred 1% Eye Drops SML, Lotepred LS 0.2%E/D5ML, Lotepred T, Nepalact OD Eye Drops 3ML, Nepalact-Z, Toba-F & Nepalact E/D 5ML."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/I9GNHCo
via IFTTT

TPG, Permira emerge as frontrunners in Rs 11,000 crore Cloudnine sale

TPG Capital and Permira are leading contenders for a significant minority stake in Cloudnine. The deal is expected to value India's largest maternity and pediatric hospital chain at approximately ₹11,000 crore. Binding bids are anticipated by mid-August after due diligence is complete. This transaction will facilitate True North's full exit after over a decade of investment. Cloudnine posted ₹2,000 crore revenue and ₹300 crore Ebitda in FY26.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1wR8BM2
via IFTTT

Lupin launches generic Sugammadex injection in US

Lupin Limited announced the launch of its Sugammadex Injection in the United States. This follows approval from the US Food and Drug Administration for its abbreviated new drug application. The company's injection is claimed to be bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade in adult and pediatric surgical patients. The launch occurred on Friday, as per a regulatory filing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BKHaYWf
via IFTTT